Biomerica Inc
NASDAQ:BMRA
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Biomerica Inc
NASDAQ:BMRA
|
6.1m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
192.3B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
133.5B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
105.6B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.4B EUR |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.8B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
46B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
34B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Biomerica Inc
Glance View
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 49 full-time employees. The firm develops, patents, manufactures and markets diagnostic and therapeutic products for the early detection and monitoring of chronic diseases and other medical conditions. The firm's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the of specific bacteria, hormones, antibodies, antigens, or other substances, in a patient body, stools, or blood, saliva or nasal fluid. The firm is engaged in research and development of disruptive, patented diagnostic guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Biomerica Inc is 5.6%, which is below its 3-year median of 11.3%.
Over the last 3 years, Biomerica Inc’s Gross Margin has decreased from 16% to 5.6%. During this period, it reached a low of 5.6% on Nov 30, 2025 and a high of 16.8% on Aug 31, 2023.
